Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.

6522 Background: Phase II multicenter, single-arm (MDS-003) and phase III multicenter, randomized, placebo-controlled (MDS-004) studies assessed LEN efficacy and safety in RBC transfusion dependent pts with IPSS Low-/Int-1-risk del5q MDS. Baseline (BL) thrombocytopenia (associated with reduced cumulative dosing) and transfusion burden > 4 units/8 wks were… (More)